The Compound
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring tripeptide-copper complex first discovered in human plasma in the 1970s. Unlike many research peptides, GHK-Cu is present endogenously — your body produces it — with concentrations declining significantly with age. Plasma levels at age 20 are roughly 200 ng/mL, dropping to approximately 80 ng/mL by age 60.
This age-related decline, combined with the compound's demonstrated role in tissue repair processes, has made it one of the most studied peptides in the dermatology and regenerative medicine literature. It already appears in numerous commercially available skincare products as Copper Tripeptide-1, and its topical use has a well-established safety profile.
Mechanism of Action
GHK-Cu operates through multiple pathways simultaneously. The copper ion serves as an essential cofactor for lysyl oxidase and lysyl hydroxylase — enzymes critical for collagen cross-linking and structural stability. The peptide component modulates gene expression, with research demonstrating effects on genes involved in extracellular matrix remodeling, inflammation, and antioxidant defense.
Published research has documented that GHK-Cu stimulates collagen types I and III synthesis (up to 70% increase in laboratory studies), upregulates VEGF expression promoting angiogenesis, downregulates pro-inflammatory cytokines including IL-1β and TNF-α, enhances superoxide dismutase (SOD) activity reducing oxidative stress, stimulates fibroblast proliferation and keratinocyte migration, and increases decorin expression (a proteoglycan involved in tissue remodeling).
Skin and Anti-Aging Research
The dermatological research base for GHK-Cu is substantial and includes human data. Clinical studies have documented improvements in skin firmness, elasticity, and clarity; reduction in fine lines and wrinkle depth; improved skin barrier function; reduced photodamage and hyperpigmentation; and increased skin thickness in aged skin.
These effects have been validated in controlled human studies using topical GHK-Cu preparations, giving the compound stronger clinical backing for dermatological applications than most peptides in the research space.
Wound Healing
GHK-Cu's wound healing properties are documented across multiple animal models. Published studies show accelerated wound closure and contraction, improved take rates for transplanted skin grafts, increased blood vessel formation at wound sites, and systemic wound healing effects when administered remotely from the wound site. The compound has been incorporated into hydrogel dressing systems for wound care applications, with preclinical data showing antibacterial effects and sustained drug release.
Hair Growth
GHK-Cu has been studied for hair follicle stimulation, with research demonstrating increased hair growth and thickness, enlarged hair follicle size, and extension of the growth (anagen) phase of the hair cycle. These findings have supported the inclusion of copper peptides in hair care products, though the evidence for injectable GHK-Cu's hair effects is primarily preclinical.
Regulatory Status
GHK-Cu occupies a unique regulatory position. Topical formulations are widely available commercially and have FDA-cleared cosmetic applications. Injectable GHK-Cu, however, was included in the broader peptide restrictions. It has been removed from the Category 2 list and is expected to be reviewed by the PCAC by early 2027, following a separate evaluation path from the July 2026 meeting. Non-injectable GHK-Cu is following yet another evaluation timeline, anticipated before February 2027.
Safety
Topical GHK-Cu has an established safety profile spanning decades of commercial use. For injectable administration, the safety data is more limited but generally favorable in preclinical models. As a naturally occurring human peptide, GHK-Cu benefits from the assumption of endogenous compatibility, though exogenous administration at supraphysiological doses is a different proposition than the body's own production.